Amenamevir is an antiviral agent used for the treatment of herpes zoster (shingles). It functions as a helicase-primase inhibitor, disrupting viral DNA replication and thereby reducing the severity and duration of shingles outbreaks. Amenamevir is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2. Amenamenir stabilizes the interaction between the helicase-primase and its DNA substrates, preventing the progression through helicase or primase catalytic cycles, thus interfering with viral DNA replication and viral growth. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include amenamevirum, Amenalief (TN) and ASP 2151. Its PubChem CID is 11397521.
Amenamevir
| CAS No | 841301-32-4 |
|---|---|
| Molecular Formula | C24H26N4O5S |
| Molecular Weight | 482.56 g/mol |
| Synonyms | N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Amenamevir is an antiviral agent used for the treatment of herpes zoster (shingles). It functions as a helicase-primase inhibitor, disrupting viral DNA replication and thereby reducing the severity and duration of shingles outbreaks.
The listed CAS number is 841301-32-4.
The listed molecular formula is C24H26N4O5S.
The listed molecular weight is 482.56 g/mol.
N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide.
The source lists amenamevirum, Amenalief (TN) and ASP 2151.